Chung‐Han Lee

Also affiliated with Yonsei University, Cornell University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

2.8Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1283

Top 12%

1.8DataRank

Top 12%68 citations

Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Düzgöl, Samuel A. Funt +18 more

Papers

Driven by 30 papers — median percentile 84. Top paper: “Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study”.

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00241-2

N/A

5.2DataRank · unranked

186 citations

Amishi Y. Shah, Drew Rasco, Arpit Rao, Matthew H. Taylor, Christopher Di Simone +23 more

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.01485

N/A

3.3DataRank · unranked

100 citations

Michael Lattanzi, Karissa Whiting, Hikmat Al‐Ahmadie, Colleen Quinlan, Min Yuen Teo +34 more

Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1283

Top 12%

1.8DataRank

Top 12%68 citations

Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Düzgöl, Samuel A. Funt +18 more

Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

Cancer(2020)10.1002/cncr.33148

N/A

1.2DataRank · unranked

38 citations

Yasser Ged, Chung‐Han Lee, Andrea Knežević, Ana M. Molina, Ying‐Bei Chen +13 more

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

Molecular Cancer Research(2021)10.1158/1541-7786.mcr-21-0053

N/A

1.2DataRank · unranked

33 citations

Renzo G. DiNatale, Diego Chowell, Chirag Krishna, Vladimir Makarov, Cristina Valero +21 more

Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4058

Top 20%

1.0DataRank

Top 20%23 citations

Renzo G. DiNatale, Phillip M. Rappold, Christopher J. Fong, Francisco Sánchez-Vega, Andrew W. Silagy +15 more

Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas

European Urology Focus(2022)10.1016/j.euf.2021.12.002

N/A

0.835DataRank · unranked

27 citations

Cerise Tang, Mark Zucker, Kelly N. Fitzgerald, Renzo G. DiNatale, Phillip M. Rappold +15 more

PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine

Nature Immunology(2022)10.1038/s41590-022-01274-3

N/A

0.663DataRank · unranked

82 citations

David A. Knorr, Laura A. Vella, Luisa Victoria Silva, Lakshmi Chilukuri, Sokratis A. Apostolidis +23 more

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009495

N/A

0.615DataRank · unranked

19 citations

Opeyemi A. Jegede, Elizabeth R. Plimack, Thomas Powles, Robert J. Motzer, Nizar M. Tannir +13 more

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2283

N/A

0.609DataRank · unranked

57 citations

Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer +16 more

Immunometabolic coevolution defines unique microenvironmental niches in ccRCC

Cell Metabolism(2023)10.1016/j.cmet.2023.06.005

N/A

0.483DataRank · unranked

24 citations

Amy Xie, Eric Minwei Liu, Fengshen Kuo, Min‐Soo Kim, Renzo G. DiNatale +15 more

Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors

The Oncologist(2025)10.1093/oncolo/oyaf017

N/A

0.473DataRank · unranked

11 citations

Yonina R. Murciano‐Goroff, Antoine Desîlets, Guilherme Harada, Michael A. Postow, Margaret K. Callahan +9 more

A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer

European Urology Oncology(2023)10.1016/j.euo.2023.10.017

N/A

0.416DataRank · unranked

15 citations

Sahil D. Doshi, Andrea Knežević, Joshua Chaim, Ying‐Bei Chen, Rachel Jacobi +14 more

Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.2574

N/A

0.241DataRank · unranked

4 citations

Christopher A. Desjardins, Paul A. Giardina, Kankana Bardhan, Swarna Pandian, Keith Halley +14 more

A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma

European Urology Oncology(2025)10.1016/j.euo.2025.03.010

N/A

0.104DataRank · unranked

1 citations

Sahil D. Doshi, Andrea Knežević, Rachel Jacobi, Hyung Jun Woo, David H. Aggen +13 more

A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4558

N/A

0DataRank · unranked

0 citations

Minwei Liu, Fengshen Kuo, Ritesh R. Kotecha, Chung‐Han Lee, Martin H. Voss +4 more

Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.04.28.489873

N/A

0DataRank · unranked

2 citations

Mark Zucker, Min‐Soo Kim, Paul Russo, Jonathan Coleman, Chung‐Han Lee +6 more

Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma

Frontiers in Oncology(2022)10.3389/fonc.2022.910147

N/A

0DataRank · unranked

14 citations

Mark Zucker, Min‐Soo Kim, Paul Russo, Jonathan Coleman, Chung‐Han Lee +6 more

Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e16519

N/A

0DataRank · unranked

0 citations

Min Yuen Teo, Samuel A. Funt, Chung‐Han Lee, David H. Aggen, Neha Ratna +11 more

Genomic ancestry in kidney cancer: Correlations with clinical and molecular features

Cancer(2023)10.1002/cncr.35074

N/A

0DataRank · unranked

12 citations

Andrea Knežević, Kanika Arora, Chaitanya Bandlamudi, Fengshen Kuo, Maria I. Carlo +12 more

Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma

Urologic Oncology Seminars and Original Investigations(2023)10.1016/j.urolonc.2023.12.003

N/A

0DataRank · unranked

6 citations

Lennert Eismann, Charlie White, Juan Arroyave Villada, Sari Khaleel, Irina Ostrovnaya +13 more

Data from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

(2023)10.1158/1541-7786.c.6545243

N/A

0DataRank · unranked

2 citations

Renzo G. DiNatale, Diego Chowell, Chirag Krishna, Vladimir Makarov, Cristina Valero +21 more

Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4598

N/A

0DataRank · unranked

2 citations

Neha Ratna, David Gavrilov, Cihan Düzgöl, Mahnoor Akhlaq, Min Yuen Teo +15 more

Data from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

(2023)10.1158/1078-0432.c.6532988.v1

N/A

0DataRank · unranked

0 citations

Alejandro Sánchez, Sujata Patil, Andrea Knežević, Emily Stein, Stacey Petruzella +15 more

Data from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

(2023)10.1158/1078-0432.c.6532988

N/A

0DataRank · unranked

0 citations

Alejandro Sánchez, Sujata Patil, Andrea Knežević, Emily Stein, Stacey Petruzella +15 more

Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4559

N/A

0DataRank · unranked

0 citations

Andrew R. Schroeder, Semanti Mukherjee, Yelena Kemel, Ritesh R. Kotecha, Chung‐Han Lee +12 more

Evaluation of germline genetic testing criteria in early-onset kidney cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.296

N/A

0DataRank · unranked

0 citations

Rania Sheikh, Ritesh R. Kotecha, Yelena Kemel, Aliya Khurram, Peter A. Reisz +15 more

Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials

Clinical Genitourinary Cancer(2024)10.1016/j.clgc.2024.102268

N/A

0DataRank · unranked

0 citations

Andrea Knežević, Carlene Gonzalez, Patricia Fischer, ROBERT GOODMAN, Suzanne Gornell +9 more

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma

European Urology Open Science(2021)10.1016/j.euros.2021.06.008

N/A

0DataRank · unranked

4 citations

Yin Wan, Alan D. Smith, Ran Xie, Robert J. Motzer, Chung‐Han Lee

Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing

European Urology Oncology(2021)10.1016/j.euo.2021.09.005

N/A

0DataRank · unranked

39 citations

Rania Sheikh, Ritesh R. Kotecha, Yelena Kemel, Peter A. Reisz, Andrew T. Lenis +22 more

Chung‐Han Lee

Indexed papers

Top data-sharing exemplar

Papers